NCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
Clinical Trials
146 trialsNCT04741789 2026-03-16
Managed Access Programs for INC280, Capmatinib
Novartis
No longer available
NCT06404034 2026-03-04
Expanded Access to Gallium Maltolate (GaM)
Imaging Biometrics, LLC
No longer available
NCT07399015 2026-02-18
Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC
Endevica Bio
No longer available
NCT06439966 2026-02-12
Expanded Access to ABBV-787
AbbVie
No longer available
NCT06195514 2026-01-30
Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)
Takeda
No longer available
NCT03756311 2026-01-23
Expanded Access to NanoPac
NanOlogy, LLC
No longer available
NCT04060628 2026-01-23
Expanded Access to NanoDoce
NanOlogy, LLC
No longer available
NCT06063746 2026-01-08
Compassionate Use of Vidutolimod
Regeneron Pharmaceuticals
No longer available
NCT06841874 2025-12-24
Tale EAP
Nuvation Bio Inc.
No longer available
NCT04489433 2025-12-18
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
Novartis
No longer available
NCT06590480 2025-12-18
RPL-EAP-001
Replimune Inc.
No longer available
NCT05161598 2025-12-16
Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)
Janssen Research & Development, LLC
No longer available
NCT05503550 2025-12-16
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
No longer available
NCT03523338 2025-12-10
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
No longer available
NCT05269771 2025-11-05
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Novartis
No longer available
NCT04087889 2025-09-29
Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
Hope Biosciences Research Foundation
No longer available
NCT05918913 2025-09-05
Expanded Access Program for Revumenib
Syndax Pharmaceuticals
No longer available
NCT04667234 2025-08-13
Expanded Access of Sotorasib
Amgen
No longer available
NCT04681248 2025-08-03
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Leap Therapeutics, Inc.
No longer available
NCT04313075 2025-07-15
A Compassionate Use Study of Leronlimab in Breast Cancer
CytoDyn, Inc.
No longer available
NCT04452994 2025-06-13
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
Janssen Research & Development, LLC
No longer available
NCT06099639 2025-06-08
Medical Access Program for Patritumab Deruxtecan
Daiichi Sankyo
No longer available
NCT03593499 2025-05-31
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
Biogen
No longer available
NCT04578444 2025-05-25
An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
Jazz Pharmaceuticals
No longer available
NCT04087876 2025-04-06
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Basilea Pharmaceutica
No longer available
NCT03414489 2025-03-18
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
RedHill Biopharma Limited
No longer available
NCT05683548 2025-02-17
RCAP
Replicor Inc.
No longer available
NCT05238311 2025-02-04
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Pfizer
No longer available
NCT04948398 2025-02-03
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Janssen Research & Development, LLC
No longer available
NCT04507919 2024-11-12
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
Novartis
No longer available
NCT04544202 2024-11-12
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
Novartis
No longer available
NCT05518838 2024-11-08
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Oblato, Inc.
No longer available
NCT04714086 2024-10-24
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
No longer available
NCT04052854 2024-10-23
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
BeiGene
No longer available
NCT04225429 2024-10-01
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
Ipsen
No longer available
NCT05936216 2024-10-01
TVI-Brain-1 in Expanded Access Patient
TVAX Biomedical
No longer available
NCT03420430 2024-09-25
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
Genelux Corporation
No longer available
NCT05462639 2024-08-09
MAGNETISMM17
Pfizer
No longer available
NCT05551013 2024-08-09
Treatment of Recurrent GBM With APG-157 Via Expanded Access
Aveta Biomics, Inc.
No longer available
NCT05219266 2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available
NCT02473497 2024-06-26
Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
Pfizer
No longer available
NCT03592576 2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available
NCT04321694 2024-04-25
Expanded Access for KHK2455
Kyowa Kirin Co., Ltd.
No longer available
NCT04814732 2024-04-12
Expanded Access Program of Surufatinib
Hutchmed
No longer available
NCT03874455 2024-03-22
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
No longer available
NCT04757259 2024-03-19
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
Alexion Pharmaceuticals, Inc.
No longer available
NCT05225259 2024-02-28
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Eli Lilly and Company
No longer available
NCT05683470 2024-02-21
Expanded Access RBS2418 Treatment
Riboscience, LLC.
No longer available
NCT05627466 2024-02-15
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Gilead Sciences
No longer available